Investments
40Portfolio Exits
17Funds
6About Sectoral Asset Management
Sectoral Asset Management is an SEC-registered investment advisor based in Montreal whose focus is managing global equity portfolios by industry. Sectoral has also launched an alternative investment fund that offers an attractive exposure to the growing healthcare/biotech sector through both long and short positions.
Sectoral Asset Management Headquarter Location
1000 Sherbrooke Street Suite 2120
H3A 3G4,
Canada
Expert Collections containing Sectoral Asset Management
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Sectoral Asset Management in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest Sectoral Asset Management News
Jun 8, 2022
Mineralys Therapeutics, Inc. , a Philadelphia, PA-based clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension, closed a $118m Series B financing. The round was led by RA Capital Management and Andera Partners with participation from new investors included RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Capital, HealthCor Management and Boulder Ventures. Existing investors, including founding investment firm Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments and Adams Street Partners also participated. As part of the Series B financing, Olivier Litzka, PhD, Partner, Andera Partners and Derek DiRocco, Partner, RA Capital Management will join the Mineralys Board of Directors. The company plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-HTN, for patients with uncontrolled hypertension. Founded by Catalys Pacific and led by Jon Congleton, Chief Executive Officer, and BT Slingsby MD, PhD, MPH, Founder & Executive Chairman, Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapy for the treatment of hypertension. The company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. FinSMEs 08/06/2022
Sectoral Asset Management Investments
40 Investments
Sectoral Asset Management has made 40 investments. Their latest investment was in Mineralys Therapeutics as part of their Series B on June 6, 2022.
Sectoral Asset Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/8/2022 | Series B | Mineralys Therapeutics | $118M | Yes | 6 | |
5/4/2022 | Series C | Apnimed | $62.5M | Yes | 3 | |
1/25/2022 | Series D | Magnolia Medical Technologies | $46M | Yes | 2 | |
11/3/2021 | Series B | |||||
9/23/2021 | Series A |
Date | 6/8/2022 | 5/4/2022 | 1/25/2022 | 11/3/2021 | 9/23/2021 |
---|---|---|---|---|---|
Round | Series B | Series C | Series D | Series B | Series A |
Company | Mineralys Therapeutics | Apnimed | Magnolia Medical Technologies | ||
Amount | $118M | $62.5M | $46M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 6 | 3 | 2 |
Sectoral Asset Management Portfolio Exits
17 Portfolio Exits
Sectoral Asset Management has 17 portfolio exits. Their latest portfolio exit was eFFECTOR Therapeutics on May 27, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
5/27/2021 | Acq - Pending | 2 | |||
2/24/2021 | Acquired | 4 | |||
10/30/2020 | IPO | Public | 1 | ||
Date | 5/27/2021 | 2/24/2021 | 10/30/2020 | ||
---|---|---|---|---|---|
Exit | Acq - Pending | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 4 | 1 |
Sectoral Asset Management Fund History
6 Fund Histories
Sectoral Asset Management has 6 funds, including New Emerging Medical Opportunities Fund IV.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
5/26/2020 | New Emerging Medical Opportunities Fund IV | $96M | 1 | ||
7/31/2015 | New Emerging Medical Opportunities Fund III | ||||
10/31/2013 | New Emerging Medical Opportunities Fund II | ||||
12/31/2007 | New Emerging Medical Opportunities Fund I | ||||
New Emerging Medical Opportunities Funds II |
Closing Date | 5/26/2020 | 7/31/2015 | 10/31/2013 | 12/31/2007 | |
---|---|---|---|---|---|
Fund | New Emerging Medical Opportunities Fund IV | New Emerging Medical Opportunities Fund III | New Emerging Medical Opportunities Fund II | New Emerging Medical Opportunities Fund I | New Emerging Medical Opportunities Funds II |
Fund Type | |||||
Status | |||||
Amount | $96M | ||||
Sources | 1 |
Sectoral Asset Management Team
6 Team Members
Sectoral Asset Management has 6 team members, including current Chief Executive Officer, Jerome G Pfund.
Name | Work History | Title | Status |
---|---|---|---|
Michael Sjöström | Founder | Current | |
Jerome G Pfund | Chief Executive Officer | Current | |
Jean Bãƒâ©rard | Chief Financial Officer | Current | |
Marc-André Marcotte | Chief Operating Officer | Current | |
Elizabeth Lazaro | Managing Director | Current |
Name | Michael Sjöström | Jerome G Pfund | Jean Bãƒâ©rard | Marc-André Marcotte | Elizabeth Lazaro |
---|---|---|---|---|---|
Work History | |||||
Title | Founder | Chief Executive Officer | Chief Financial Officer | Chief Operating Officer | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.